Dr Reddy's Labs launches authorized generic version of NitroDur® (nitroglycerin) Transdermal Infusion System in US

Hyderabad and Princeton: Dr Reddy's Laboratories Ltd. has announced the launch of an authorized generic version of NitroDur® (nitroglycerin) Transdermal Infusion System.

The combined market for all Nitrogylcerin Transdermal Patch products had U.S. sales of approximately $14.7 million MAT for the most recent twelve months ending in January 2020 according to IQVIA Health*.

Dr. Reddy's Nitroglycerin Transdermal Infusion System is available in four dosage strengths: 0.1 mg/hr, 0.2 mg/hr, 0.4 mg/hr, and 0.6 mg/hr, each in a box of 30 count.

NitroDur® is a trademark of USpharma Ltd.

Dr Reddy's Laboratories Ltd. is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.

Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics, and Proprietary Products- Dr Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, and differentiated formulations.

Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. Dr Reddy's operates in markets across the globe. Its major markets include – USA, India, Russia & CIS countries, and Europe.

Read also: Dr Reddy's Labs launches Amphetamine Sulfate Tablets USP in US Market